Business combination, contingent consideration, commercial milestone payments, payable.

No definition available.

Name:	goss_BusinessCombinationContingentConsiderationCommercialMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business combination, contingent consideration, development and regulatory milestone payments, payable.

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationDevelopmentAndRegulatoryMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business combination, contingent consideration, development and sales milestones, payable.

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationRegulatoryDevelopmentAndSalesMilestonesPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business combination, contingent consideration, sales milestone payments, payable.

+ References

No definition available.

+ Details

Name:	goss_BusinessCombinationContingentConsiderationSalesMilestonePaymentsPayable
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Product license term.

+ References

No definition available.

+ Details

Name:	goss_ProductLicenseTerm
Namespace Prefix:	goss_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	goss_UpfrontPayment
Namespace Prefix:	goss_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The net amount, measured at acquisition-date fair value, of all the assets acquired and liabilities assumed that arise from contingencies and were recognized by the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationAssetsAndLiabilitiesArisingFromContingenciesAmountRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentGBZeroZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=goss_PulmokineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=goss_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentGBZeroZeroTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=goss_InProcessResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=goss_AABiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=goss_SeriesSeedConvertiblePreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=goss_AerpioPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentGBZeroZeroFourMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=goss_AdhaerePharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=goss_InProcessResearchAndDevelopmentGBOneTwoSevenFiveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Acquisitions and Contingent Consideration - Additional Information (Details) - USD ($)								3 Months Ended
	Sep. 30, 2018	Sep. 21, 2018	Jun. 30, 2018	Jan. 31, 2018	Jan. 04, 2018	Oct. 31, 2017	Oct. 02, 2017	Mar. 31, 2019	Mar. 31, 2018	Jun. 24, 2018
Business Acquisition [Line Items]
In process research and development								$ 1,000,000	$ 20,898,000
GB001
Business Acquisition [Line Items]
In process research and development									$ 19,148,000
Pulmokine, Inc. \| License Agreement \| GB002
Business Acquisition [Line Items]
Product license term							10 years
Milestones accrued								0
Pulmokine, Inc. \| License Agreement \| GB002 \| IPR&D
Business Acquisition [Line Items]
Upfront payment						$ 5,500,000
Pulmokine, Inc. \| License Agreement \| GB002 \| Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable							$ 63,000,000
Commercial milestone payments, payable							45,000,000
Sales milestone payments, payable							$ 190,000,000
AA Biopharma Inc. \| GB001
Business Acquisition [Line Items]
In process research and development				$ 19,300,000
AA Biopharma Inc. \| GB001 \| Common Stock
Business Acquisition [Line Items]
Business acquisition, aggregate number of shares issued					1,101,278
AA Biopharma Inc. \| GB001 \| Series Seed Convertible Preferred Stock
Business Acquisition [Line Items]
Business acquisition, aggregate number of shares issued					20,000,000
Aerpio Pharmaceuticals, Inc. \| License Agreement \| GB004
Business Acquisition [Line Items]
Milestones accrued								0
Upfront payment, purchase consideration paid			$ 20,000,000
Aerpio Pharmaceuticals, Inc. \| License Agreement \| GB004 \| Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable										$ 55,000,000
Commercial milestone payments, payable										85,000,000
Sales milestone payments, payable										$ 260,000,000
Adhaere Pharmaceuticals, Inc. \| GB1275
Business Acquisition [Line Items]
Milestones accrued								$ 0
In process research and development	$ 7,500,000
Upfront payment, purchase consideration paid		$ 7,500,000
Adhaere Pharmaceuticals, Inc. \| GB1275 \| Maximum
Business Acquisition [Line Items]
Regulatory, development and sales milestones payable		$ 62,000,000